Abstract

Genomic analysis of individual patients is now affordable and therapies targeted to specific molecular aberrations are being tested in clinical trials. However, even highly-specialized physicians at leading academic centers are not equipped to apply genomic information available in publically available sources to clinical- decision-making concerning individual patients. Our central hypothesis is that we can develop informatics tools to support personalized cancer treatment as standard of care rather than one off exceptions. We will: 1) implement a bioinformatics pipeline for processing molecular data into actionable profiles, 2) create and maintain a database of therapeutic implications of common genomic aberrations using automated processing of publically-available sources and 3) develop tools to summarize and present patient-specific advice to clinicians. These tools will be based on existing technologies and publicly available data sources. Once tested, we will make these tools available via appropriate open source license.

Public Health Relevance

Genomic analysis of individual patients is now affordable and therapies targeted to specific molecular aberrations are being tested in clinical trials. In this project, we will develop informatics tools to support personalized cancer treatment as 'standard of care' rather than 'one off' exception.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA180964-03
Application #
8904309
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Ossandon, Miguel
Project Start
2013-09-01
Project End
2016-08-31
Budget Start
2015-09-01
Budget End
2016-08-31
Support Year
3
Fiscal Year
2015
Total Cost
Indirect Cost

  Institution

Name
University of Texas Health Science Center Houston
Department
Type
Sch Allied Health Professions
DUNS #
800771594
City
Houston
State
TX
Country
United States
Zip Code
77225

  Publications

Meric-Bernstam, Funda; Zheng, Xiaofeng; Shariati, Maryam et al. (2018) Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precis Oncol 2018:
Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194
Sen, Shiraj; Hess, Kenneth; Hong, David S et al. (2018) Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. Br J Cancer 118:763-769
Brusco, Lauren L; Wathoo, Chetna; Mills Shaw, Kenna R et al. (2018) Physician interpretation of genomic test results and treatment selection. Cancer 124:966-972
Kurnit, Katherine C; Dumbrava, Ecaterina E Ileana; Litzenburger, Beate et al. (2018) Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clin Cancer Res 24:2719-2731
Johnson, Amber; Khotskaya, Yekaterina B; Brusco, Lauren et al. (2017) Clinical Use of Precision Oncology Decision Support. JCO Precis Oncol 2017:
Arango, Natalia Paez; Brusco, Lauren; Mills Shaw, Kenna R et al. (2017) A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget 8:41806-41814
Goldstein, Jennifer B; Tang, Chad; Hess, Kenneth R et al. (2017) Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget 8:87163-87173
Kurnit, Katherine C; Bailey, Ann M; Zeng, Jia et al. (2017) ""Personalized Cancer Therapy"": A Publicly Available Precision Oncology Resource. Cancer Res 77:e123-e126
Meric-Bernstam, F; Brusco, L; Daniels, M et al. (2016) Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Ann Oncol 27:795-800

Showing the most recent 10 out of 35 publications